China SXT Pharmaceuticals Profit Margin

China SXT Pharmaceuticals (SXTC) currently reports a profit margin of -2.91% as of March 2026. That compares with 70.0% in the prior-year period — down 515.3% year over year. That is below the Consumer Discretionary sector average of 9.32%. Use the charts on this page to explore China SXT Pharmaceuticals's profit margin history and peer comparisons.

China SXT Pharmaceuticals's profit margin decreased from 70.0% to -2.91% — a 515.3% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

China SXT Pharmaceuticals's profit margin of -2.91% is lower than the Consumer Discretionary sector average of 9.32%. That is roughly 3219.1% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but China SXT Pharmaceuticals's current -2.91% should be judged against Consumer Discretionary norms (sector average: 9.32%) and against SXTC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -2.91%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Consumer Discretionary average is 9.32%. From there, open related valuation or income-statement pages for China SXT Pharmaceuticals, and consider following SXTC for alerts when major investors trade the stock.